Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05475210 · ClinicalTrials.gov registry record · Phase 1
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Tumors, sponsored by Molecular Targeting Technologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05475210: Recruiting Phase 1 study of Neuroendocrine Tumors, sponsored by Molecular Targeting Technologies.
NCT05475210 is a Phase 1 study of Neuroendocrine Tumors that is actively recruiting participants, run by Molecular Targeting Technologies. The registered enrollment target is 9 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05475210, a Phase 1 study of Neuroendocrine Tumors, is actively recruiting participants, sponsored by Molecular Targeting Technologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
Conditions Studied
Interventions
- DRUG 177Lu-DOTA-EB-TATE
- OTHER Amino Acid Solution
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-06-18 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 1 |
What NCT05475210 shows while recruiting
NCT05475210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which 177Lu-DOTA-EB-TATE is the first listed.
NCT05475210 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05475210 about?
NCT05475210 is a clinical study titled "177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors". This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
What is the current status of trial NCT05475210?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-06-18. Estimated completion is 2025-03-30.
What conditions does trial NCT05475210 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT05475210?
The interventions under investigation include: 177Lu-DOTA-EB-TATE (DRUG), Amino Acid Solution (OTHER).
Who is sponsoring clinical trial NCT05475210?
This trial is sponsored by Molecular Targeting Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05475210 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05475210's enrollment target sits among peer trials
9 52nd of 52 higher than 1 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI